PROTACs- a game-changing technologyKonstantinidou, M., Li, J., Zhang, B., Wang, Z., Shaabani, S., Ter Brake, F., Essa, K. & Dömling, A., 2019, In : Expert Opinion on Drug Discovery. 14, 12, p. 1255-1268 14 p.
Research output: Contribution to journal › Article › Academic › peer-review
Introduction: Proteolysis - targeting chimeras (PROTACs) have emerged as a new modality with the potential to revolutionize drug discovery. PROTACs are heterobifunctional molecules comprising of a ligand targeting a protein of interest, a ligand targeting an E3 ligase and a connecting linker. The aim is instead of inhibiting the target to induce its proteasomal degradation. Areas covered: PROTACs, due to their bifunctional design, possess properties that differentiate them from classical inhibitors. A structural analysis, based on published crystal aspects, kinetic features and aspects of selectivity are discussed. Specific types such as homoPROTACs, PROTACs targeting Tau protein and the first PROTACs recently entering clinical trials are examined. Expert opinion: PROTACs have shown remarkable biological responses in challenging targets, including an unprecedented selectivity over protein family members and even efficacy starting from weak or unspecific binders. Moreover, PROTACs are standing out from classical pharmacology by inducing the degradation of the target protein and not merely its inhibition. However, there are also challenges in the field, such as the rational structure optimization, the evolution of computational tools, limited structural data and the greatly anticipated clinical data. Despite the remaining hurdles, PROTACs are expected to soon become a new therapeutic category of drugs.
|Number of pages||14|
|Journal||Expert Opinion on Drug Discovery|
|Early online date||20-Sep-2019|
|Publication status||Published - 2019|
- Degradation, PROTAC, structural analysis, article, chimera, clinical trial (topic), controlled study, crystal, drug efficacy, human, protein degradation, protein family, structure analysis, endogenous compound, proteasome, ubiquitin protein ligase
No data available